News Releases


BioSante Pharmaceuticals, Inc. To Present at Two Upcoming Investor Conferences

LINCOLNSHIRE, Illinois (May 18, 2011) – BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) will be presenting at two upcoming investors conferences on May 24, 2011.

Stephen M. Simes, BioSante’s president & CEO, will speak on May 24, 2011 at 11:00 am London time at the UBS Global Specialty Pharmaceutical Conference being held on May 24-25, 2011 at UBS offices in London. The webcast will be archived after the live event and will be available for 180 days.

Phillip B. Donenberg, BioSante’s senior vice president of finance and CFO, will speak on May 24, 2011 at 11:30 am PT at the 7th Annual Spring Growth Stock Conference hosted by Security Research Associates, Inc. The conference will be held on Tuesday, May 24th at the Omni Hotel in San Francisco.

Both speakers will provide an overview of BioSante, as well as an update on the LibiGel® (testosterone gel) Phase III clinical development program.

About BioSante Pharmaceuticals, Inc.

BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante’s lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment.

BioSante’s first FDA-approved product is Elestrin™ (estradiol gel) indicated for the treatment of hot flashes associated with menopause, marketed in the U.S. by Azur Pharma, BioSante’s licensee. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other BioSante products are Bio-T-Gel™, a testosterone gel for male hypogonadism, for which an NDA is pending with a PDUFA date of November 14, 2011, licensed to Teva Pharmaceuticals, and an oral contraceptive in Phase II clinical development using BioSante patented technology. Additional information is available online at:


For more information please contact:

For Media:
Harris D. McKinney, Inc.
Alan Zachary
(312) 506-5220

For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953